Novartis | NOVN - Beneficio Operativo

Precio De Mercado
121.72
Cambio Diario
1.90 1.59%
Mensual
-6.34%
Anual
23.67%
Q1 Expectativa
116.14




Beneficio Operativo Cambio Fecha
AbbVie USD 5.81B 1.23B 2025-12
Alcon AG USD 313M 19M 2025-12
Almirall EUR 30.23M 12.8M 2025-12
Amgen USD 3.96B 464M 2025-12
AstraZeneca USD 2.97B 4.48B 2025-12
Autolus Therapeutics Ltd USD -72.47M 845K 2025-12
Bayer EUR 1.11B 1.65B 2025-12
Biogen USD 659.6M 192.2M 2025-09
Bristol-Myers Squibb USD 4.2B 562M 2025-12
Eli Lilly USD 8.99B 599.9M 2025-12
Fresenius EUR 713M 139M 2025-12
Fresenius Medical Care EUR 663M 213.06M 2025-12
Galapagos EUR 780.56M 822.23M 2025-12
Genmab DKK 260M 199M 2025-12
Gilead Sciences USD 2.96B 551M 2025-12
GlaxoSmithKline GBP 1.44B 1.35B 2025-12
GRIFOLS EUR 275.38M 76.74M 2025-12
Hikma Pharmaceutical USD 348M 161M 2025-12
J&J USD 5.59B 1.81B 2025-12
Lonza CHF 673M 243M 2025-06
Merck EUR 474M 738M 2025-12
Merck USD 6.24B 318M 2025-12
Novartis USD 4.06B 437M 2025-12
Novartis USD 4.06B 521M 2025-12
Novo Nordisk DKK 32.38B 1.7B 2025-12
Orion EUR 328.2M 207.2M 2025-12
Pfizer USD 4.65B 3.99B 2025-12
Philips EUR 719M 390M 2025-12
Recordati EUR 278.23M 112.58M 2025-12
Regeneron Pharmaceuticals USD 898.6M 211.3M 2025-12
Roche Holding CHF 9.56B 3.8B 2025-12
Sanofi EUR 1.7B 2.17B 2025-12
UCB EUR 1.29B 571M 2025-12